Basit öğe kaydını göster

dc.contributor.authorBaşaran, Özcan
dc.contributor.authorBaşaran, Nesrin Filiz
dc.contributor.authorÇekic, Edip Güvenç
dc.contributor.authorAltun, İbrahim
dc.contributor.authorDoğan, Volkan
dc.contributor.authorMert, Gurbet Özge
dc.contributor.authorBiteker, Murat
dc.date.accessioned2020-11-20T14:52:56Z
dc.date.available2020-11-20T14:52:56Z
dc.date.issued2017
dc.identifier.issn1076-0296
dc.identifier.issn1938-2723
dc.identifier.urihttps://doi.org/10.1177/1076029615614395
dc.identifier.urihttps://hdl.handle.net/20.500.12809/1966
dc.descriptionWOS: 000399751600011en_US
dc.descriptionPubMed ID: 26519049en_US
dc.description.abstractIntroduction: Inappropriate use of oral anticoagulants (OACs) have not been well investigatedand, however, may be frequent in real-world practice in patients with nonvalvular atrial fibrillation (NVAF). This study was designed to evaluate the prescription patterns and appropriateness of OACs in patients with NVAF in real-world clinical settings. Methods: We performed a prospective, observational study (NCT02366338). A total of 148 patients with NVAF were screened for OAC prescription. Appropriateness of prescribing was evaluated using 9 criteria of the Medication Appropriateness Index (MAI): indication, choice, dosage, modalities and practicability of administration, drug-drug interactions, drug-disease interactions, duplication, and duration. For each criterion, the evaluator has to rate whether the medication is (A) appropriate, (B) inappropriate but with limited clinical importance, and (C) inappropriate. Results: Of 148 patients, 73 (50%) were on warfarin (group 1), 39 (26%) were on rivaroxaban (group 2), and 36 (24%) were on dabigatran therapy (group 3). The MAI showed that 83% of group 1, 28% of group 2, and 47% of group 3 patients had at least 1 inappropriate criterion. Moreover, according to the choice criterion, 37% of group 1, 8% of group 2 and 5% of group 3 were rated as inappropriate, and dosage was not appropriate in 77% of group 1, 23% of group 2, and 42% of group 3. Conclusion: Inappropriate drug use is frequent among patients with NVAF not only for warfarin but also for NOACs. Although there is an apparent improvement in thromboprophylaxis of NVAF, much more effort is needed for appropriate use of OACs.en_US
dc.item-language.isoengen_US
dc.publisherSage Publications Incen_US
dc.item-rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnticoagulant Agentsen_US
dc.subjectNon-Vitamin K Antagonistsen_US
dc.subjectMedication Appropriateness Indexen_US
dc.subjectNonvalvular Atrial Fibrillationen_US
dc.titlePRescriptiOn PattERns of Oral Anticoagulants in Nonvalvular Atrial Fibrillation (PROPER study)en_US
dc.item-typearticleen_US
dc.contributor.departmentMÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorBaşaran, Özcan
dc.contributor.institutionauthorBaşaran, Nesrin Filiz
dc.contributor.institutionauthorÇekic, Edip Güvenç
dc.contributor.institutionauthorAltun, İbrahim
dc.contributor.institutionauthorDoğan, Volkan
dc.contributor.institutionauthorBiteker, Murat
dc.contributor.institutionauthorMert, Gurbet Özge
dc.contributor.institutionauthor0000-0002-1331-5365
dc.contributor.institutionauthor0000-0002-6384-6455
dc.contributor.institutionauthor0000-0002-0076-6554
dc.identifier.doi10.1177/1076029615614395
dc.identifier.volume23en_US
dc.identifier.issue4en_US
dc.identifier.startpage384en_US
dc.identifier.endpage391en_US
dc.relation.journalClinical and Applied Thrombosis-Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster